British Columbia Adds Insulins To Its Biosimilar Switching Policy
Canadian Province Says Patients Have Six Months To Make The Transition
Executive Summary
Patients taking Humalog and NovoRapid will have six months to switch to their biosimilar equivalents after British Columbia added the rapid-acting insulins to its biosimilar switching policy.